Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

Brief Summary

Official Title: “A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/- Ribavirin for 12 and 24 Weeks in Treatment-Naive Subjects With Chronic Genotype 1 HCV Infection.”

The purpose of this study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir (LDV)/sofosbuvir (SOF) fixed-dose combination (FDC) tablets with or without ribavirin (RBV) administered for 12 and 24 weeks in treatment-naive subjects with chronic genotype 1 HCV infection.

  • Study Type: Interventional
  • Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
  • Study Primary Completion Date: March 2014

Interventions Used in this Clinical Trial

  • Drug: LDV/SOF
    • LDV/SOF 90/400 mg FDC tablet administered orally once daily
  • Drug: RBV
    • RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Arms, Groups and Cohorts in this Clinical Trial

  • Experimental: LDV/SOF 12 weeks
    • LDV/SOF administered for 12 weeks
  • Experimental: LDV/SOF+RBV 12 weeks
    • LDV/SOF+RBV administered for 12 weeks.
  • Experimental: LDV/SOF 24 weeks
    • LDV/SOF administered for 24 weeks
  • Experimental: LDV/SOF+RBV 24 weeks
    • LDV/SOF+RBV administered for 24 weeks.

Outcome Measures for this Clinical Trial

Primary Measures

  • Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Study Drug (SVR12)
    • Time Frame: Posttreatment Week 12
      Safety Issue?: No
  • Incidence of Adverse Events Leading to Permanent Discontinuation From Any Study Drug
    • Time Frame: Up to 24 weeks
      Safety Issue?: No

Secondary Measures

  • Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Study Drug
    • Time Frame: Posttreatment Weeks 4 and 24
      Safety Issue?: No
  • Percentage of Participants With HCV RNA < LLOQ at Week 2
    • Time Frame: Week 2
      Safety Issue?: No
  • Percentage of Participants With HCV RNA < LLOQ at Week 4
    • Time Frame: Week 4
      Safety Issue?: No
  • Percentage of Participants With HCV RNA < LLOQ at Week 8
    • Time Frame: Week 8
      Safety Issue?: No
  • Change From Baseline in HCV RNA at Week 2
    • Time Frame: Baseline; Week 2
      Safety Issue?: No
  • Change From Baseline in HCV RNA at Week 4
    • Time Frame: Baseline; Week 4
      Safety Issue?: No
  • Change From Baseline in HCV RNA at Week 8
    • Time Frame: Baseline; Week 8
      Safety Issue?: No
  • Percentage of Participants With Virologic Failure
    • Time Frame: Baseline to posttreatment Week 24
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria

  • Age ≥ 18, with chronic genotype 1 HCV infection
  • HCV treatment-naive
  • HCV RNA > 10,000 IU/mL at screening
  • Cirrhosis determination; a liver biopsy may be required
  • Screening laboratory values within defined thresholds
  • Use of two effective contraception methods if female of childbearing potential or sexually active male

Exclusion Criteria

  • Pregnant or nursing female or male with pregnant female partner
  • Co-infection with HIV or hepatitis B virus (HBV)
  • Current or prior history of clinical hepatic decompensation
  • Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain resolved skin cancers)
  • Chronic use of systemic immunosuppressive agents
  • History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial: No

Clinical Trial Investigator Information

  • Lead Sponsor
    • Gilead Sciences
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jenny Yang, Pharm D, Study Director, Gilead Sciences

Source

Clinical Trials content is provided directly by the US National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of information about a specific clinical trial contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01701401